First human test: how kidneys handle new drug

NCT ID NCT07217886

Summary

This early-stage study aims to understand how a new drug, S-892216, behaves in the body of people with different levels of kidney function. It will enroll 40 participants, some with healthy kidneys and some with mild to severe kidney problems, including some on dialysis. The main goal is to measure drug levels in the blood and check for safety and side effects to guide future dosing.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Alliance for Multispecialty Research (AMR)-Knoxville

    RECRUITING

    Knoxville, Tennessee, 37920, United States

  • Genesis Clinical Research

    RECRUITING

    Tampa, Florida, 33603, United States

  • Global Clinical Professionals (GCP) LLC

    RECRUITING

    St. Petersburg, Florida, 33705, United States

  • Orlando Clicinal Research Center

    RECRUITING

    Orlando, Florida, 32809, United States

Conditions

Explore the condition pages connected to this study.